HOME >> BIOLOGY >> NEWS
It's feast or famine: Predators may drive lemming cycles, Science researchers say

This news release is also available in French.

New findings suggest that a special combination of predators can drive lemming populations through a four-year boom and bust cycle, which has been one of ecology's big mysteries for over half a century.

While it's a myth that lemmings hurl themselves en masse over cliffs, the reality has been nearly as bewildering for Scandinavians and others at northern high latitudes who periodically find the land awash in these small rodents. Depending on the species, populations of lemmings and their vole cousins can explode by 100 or even 1,000 times their original size and then crash on a regular basis.

The collared lemming, which lives in the high-arctic tundra, is the single prey in one of the world's simplest vertebrate predator-prey relationships. The stoat, arctic fox, snowy owl, and a seabird called the long-tailed skua all dine on this hamster-like animal.

Scientists now suggest that these four predators may be solely responsible for the four-year population cycle in eastern Greenland and possibly in many other collared lemming populations. In contrast to previous hypotheses, food or space shortages didn't appear to be involved, the researchers report in their study, which appears in the 31 October issue of the journal Science, published by AAAS, the non-profit science society

"This question of lemming cycles has been open for almost a century. Different schools have argued about this. It has been a very, very hot issue," said study author Olivier Gilg of the University of Helsinki in Finland and Center for Biology and Management of Populations (CBGP), in Montferrier, France.

The field of small mammal ecology was born in 1924, when the eminent British ecologist Charles Elton published one of his seminal papers on rodent population cycles. Researchers have been studying these cycles ever since
'"/>

Contact: Christina Smith
ccsmith@aaas.org
202-326-7088
American Association for the Advancement of Science
30-Oct-2003


Page: 1 2 3

Related biology news :

1. Subtract a gene and feasting mice add no fat
2. A feast of lobsters
3. Study: King Midas feast offered golden opportunity for fungi
4. Predators and human health
5. Predators: an overlooked player in plant-pollinator relationships
6. Predators drive evolution of virtual prey appearance
7. Research Shows How Shrimps Escape Predators
8. Broken arms and collateral damage: clues to predator-driven evolution
9. Ecology drives the worldwide distribution of human diseases
10. Espionage may have driven the evolution of bee language according to UCSD-led study in Brazil
11. Changes to insect-seeking calls of horseshoe bats may drive new species formation

Post Your Comments:
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: